Opus Genetics (IRD) Other Non Operating Income (2010 - 2026)
Opus Genetics (IRD) posted quarterly Other Non Operating Income of $844000.0 for Q1 2026, up 179.47% year-over-year from $302000.0 in Q1 2025, and down 87.31% quarter-over-quarter from $6.7 million in Q4 2025.
Powered by 
Analysis
Opus Genetics (IRD) Other Non Operating Income (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Other Non Operating Income for 12 consecutive years, with $844000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income rose 179.47% year-over-year to $844000.0; the TTM figure through Mar 2026 stood at -$1.1 million (down 121.18% YoY), while the FY2025 annual figure was $848000.0, down 81.03% from the prior year.
- Other Non Operating Income slipped to $844000.0 in Q1 2026 per IRD's latest filing, from $6.7 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $6.7 million in Q4 2025 and bottomed at -$9.5 million in Q3 2025.
- Historically, Other Non Operating Income has averaged $344923.1 across 5 years, with a median of $428000.0 in 2023.
- Annual changes were most pronounced in 2024 — Other Non Operating Income jumped 23426.32% — and 2025, when it tumbled 2072.05%.
- Opus Genetics' Other Non Operating Income stood at -$15000.0 in 2022, then surged by 226.67% to $19000.0 in 2023, then surged by 23426.32% to $4.5 million in 2024, then jumped by 48.79% to $6.7 million in 2025, then slumped by 87.31% to $844000.0 in 2026.
- Business Quant data shows IRD's Other Non Operating Income at $844000.0 in Q1 2026, $6.7 million in Q4 2025, and -$9.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.74 Mn |
| Mar 31, 2026 | -51.36 Mn |
| Dec 31, 2025 | -5.71 Mn |
| Sep 30, 2025 | -9.53 Mn |
| Jun 30, 2025 | 534,000.00 |
| Mar 31, 2025 | 2.81 Mn |
| Dec 31, 2024 | 2.82 Mn |
| Sep 30, 2024 | 483,000.00 |
| Jun 30, 2024 | 563,000.00 |
| Mar 31, 2024 | 602,000.00 |
| Dec 31, 2023 | 613,000.00 |
| Sep 30, 2023 | 456,000.00 |
| Jun 30, 2023 | 428,000.00 |
| Mar 31, 2023 | 340,000.00 |
| Dec 31, 2022 | 46,000.00 |
| Sep 30, 2022 | 7,000.00 |
| Jun 30, 2022 | 15,000.00 |
| Mar 31, 2022 | -82,000.00 |
| Sep 30, 2021 | 2,000.00 |
| Jun 30, 2021 | 1,000.00 |